| GUBRA APS DK 1 |
| Dänemark |
| Gesundheit |
| DK0062266474 / A3D9NV |
| PI3 (Frankfurt) |
| FRA:PI3, ETR:PI3, PI3:GR |
| - |
| https://www.gubra.dk/ |
|
Gubra A/S is a biotechnology company specializing in preclinical contract research and peptide-based drug discovery, primarily targeting metabolic and fibrotic diseases. Headquartered in Hørsholm, Denmark, it focuses on the early stages of drug deve..
>Volltext.. |
| 756.3 Mio. EUR |
| 625.47 Mio. EUR |
| 352.44 Mio. EUR |
| 288.84 Mio. EUR |
| 225.97 Mio. EUR |
| 13.86 EUR |
| 14.36 Mio. EUR |
| 4.3 Mio. EUR |
| 228.88 Mio. EUR |
| 12.73 |
| 891.48% |
| - |
| 8.19 EUR |
| - |
| - |
| 30.06.25 - 8.186725€ |
| - |
| GUBRA |
| 22.04.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|